<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0100806'>Sepsis</z:hpo> is a stressful physical condition, and at the <z:hpo ids='HP_0011009'>acute</z:hpo> phase, overstimulation of the sympathetic <z:mp ids='MP_0008912'>nervous</z:mp> system may occur; these events have the potential to induce <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0011665'>Takotsubo cardiomyopathy</z:hpo> (TTC) is a form of <z:chebi fb="2" ids="33567">catecholamine</z:chebi>-induced <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo>, which occurs very rarely in <z:hpo ids='HP_0100806'>sepsis</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>However, TTC management in <z:e sem="disease" ids="C0010340" disease_type="Disease or Syndrome" abbrv="">critically ill</z:e> patients with <z:hpo ids='HP_0100806'>sepsis</z:hpo> may be challenging because the use of exogenous <z:chebi fb="2" ids="33567">catecholamines</z:chebi> for circulatory support might augment further TTC </plain></SENT>
<SENT sid="3" pm="."><plain>Herein, we report a rare case of TTC after <z:e sem="disease" ids="C0149801" disease_type="Disease or Syndrome" abbrv="">urosepsis</z:e>; and we point out that cardiac function may improve after <z:chebi fb="2" ids="33567">catecholamine</z:chebi> withdrawal and the application of calcium channel sensitizer <z:chebi fb="0" ids="50567">levosimendan</z:chebi> </plain></SENT>
</text></document>